Quark to File IND for Eye Disease Rx in September; New Data Shows It May Treat Glaucoma

Jul 30, 2009

Premium

This article has been updated to include comments from Quark's CEO.

Quark Pharmaceuticals expects to file an investigational new drug application for its siRNA-based eye-disease treatment QPI-1007 sometime in September, RNAi News has learned.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Breaking News

The Scan

This Week in Science

In Science this week: gene regulation changes linked to human brain evolution, and more.

Seven Steps

The New York Stem Cell Foundation's Initiative on Women in Science and Engineering working group presents seven strategies to promote gender equality in the sciences.

Arsenic Adaptation

Researchers link a genetic variation to the ability to quickly process arsenic in people living in the Andes Mountains.

NIPT Tests Find Cancer in Some Pregnant Women

A small portion of pregnant women who've undergone non-invasive prenatal testing have found out from the test that they have cancer.

Featured White Papers

Miniaturizing siRNA Transfection Using the Echo Liquid Handler

RNAi Screening in Primary Cells

Main menu